$16.78▴ 5.34%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$2.69cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-1.9%year over year
Weak
Revenue is contracting year over year.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 17% below our fair-value range
Value-trap risk
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Sarepta Therapeutics, Inc. turns 269¢ of every reported profit-dollar into real cash. Revenue is contracting year over year. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$0.34
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin3.0%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$2.18B
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
0 bullish0 neutral1 bearish
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.